Resource Essentials | VABYSMO® (faricimab-svoa)

Skip To Main Content

Practice Insights

Resource Essentials

From enrollment to distribution, access tools to support your patients – all in one place.

Clarifying Coverage

Access Solutions Enrollment

Benefit Investigation & Access Support

Reimbursement & Distribution

Coverage at a Glance

VABYSMO policies for top payer plans

Financial Assistance Tool

See which program might be right for your patients

Get started here

Financial Assistance Brochure

This brochure is designed to help your patients get the support they need to access VABYSMO

Financial Assistance Brochure (Spanish)

This brochure is designed to help your Spanish-speaking patients get the support they need to access VABYSMO

Helping Patients Understand Their Health Insurance Options

This guide provides tips and considerations to help facilitate conversations with patients about their health insurance options

Learning About Health Insurance Options

This worksheet helps your patients compare information about different health insurance plans when deciding which plan is right for them

Evaluating Insurance Options Patient Letter

This letter provides information your patients may want to think about when changing insurance, including questions patients may want to ask

Understanding Medicare

This brochure includes information about the 4 parts of Medicare, an overview of Medicare Part D costs, and a summary of the Medicare Low-Income Subsidy (LIS) Program (also known as “Extra Help”)

Choosing Your Medicare Plan

This brochure can help you explain to your patients the differences between Medicare plans, and key dates for enrollment

Choosing Your Medicare Plan Part B

This brochure can help your patients understand differences between Medicare plans, and how Medigap may offer further coverage

Medicare Supplement Insurance Flash Card

This resource provides an overview of Medicare supplement health insurance, or “Medigap”, including plan offerings and coverage benefits for the applicable year

Medicare Prescription Payment Plan (MPPP) Resource

This resource helps educate your patients about how they can manage their out-of-pocket costs through the MPPP

Online Access Solutions Enrollment

My Patient Solutions^® is an online tool to help you enroll patients in Genentech Ophthalmology Access Solutions

eSubmit Patient Consent Form

The Patient Consent Form is filled out by the patient and gives permission for Genentech to work with you and the patient's health insurance plan

Prescriber Service Form

The Prescriber Service Form is filled out by the health care provider and used to collect the patient’s health insurance and treatment information

Patient Consent Form

The Patient Consent Form is filled out by the patient and gives permission for Genentech to work with the health care provider and the patient’s health insurance plan

Prescriber Service Form

The Prescriber Service Form is filled out by the health care provider and used to collect the patient’s health insurance and treatment information

Patient Consent Form

The Patient Consent Form is filled out by the patient and gives permission for Genentech to work with the health care provider and the patient’s health insurance plan

Considerations for Composing a Letter of Medical Necessity

This guide provides tips to help you draft a letter of medical necessity. A sample letter is also included for your reference

Considerations for Composing a Sample Appeal Letter

This guide provides tips to help you draft an appeal letter. A sample letter is also included for your reference

Ophthalmology Co-pay Program Patient Brochure

Genentech's Ophthalmology Co-Pay Assistance Program, designed to help eligible commercially insured patients lower their out-of-pocket costs for treatment

Ophthalmology Co-pay Program Patient Brochure (Spanish)

Genentech's Ophthalmology Co-Pay Assistance Program, designed to help eligible commercially insured Spanish-speaking patients lower their out-of-pocket costs for treatment

Genentech Patient Foundation

Designed to provide cost-free treatment to eligible patients, who are uninsured or underinsured

Independent Co-Pay Assistance Foundations

Genentech can connect eligible patients to independent, non-profit co-pay assistance foundations that may help with out-of-pocket costs for treatment

Reimbursement Guide

A quick start guide to coverage and reimbursement for practices

Sample Billing and Coding for VABYSMO

This coding information may assist you as you submit claims for reimbursement for VABYSMO

VABYSMO Ordering Guide

Ordering and distributor information

Have further questions? Find answers to Financial FAQs

VABYSMO Access >

CONNECT WITH A CASE MANAGER

A Case Manager may assist during your patient's treatment with coverage, reimbursement and financial assistance support.

Call (833) EYEGENE/ (833) 393-4363

NEXT: Patient Printables

INDICATIONS
VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO).

IMPORTANT SAFETY INFORMATION

Contraindications
VABYSMO is contraindicated in patients with ocular or periocular infection, in patients with active intraocular inflammation, and in patients with known hypersensitivity to faricimab or any of the excipients in VABYSMO. Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema, or severe intraocular inflammation.

Warnings and Precautions
Endophthalmitis and Retinal Detachments
Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques must always be used when administering VABYSMO. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay, to permit prompt and appropriate management.

Increase in Intraocular Pressure
Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of intravitreal injection, including with VABYSMO. IOP and the perfusion of the optic nerve head should be monitored and managed appropriately.

Thromboembolic Events
Although there was a low rate of arterial thromboembolic events (ATEs) observed in the VABYSMO clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

The incidence of reported ATEs in the nAMD studies during the first year was 1% (7 out of 664) in patients treated with VABYSMO compared with 1% (6 out of 662) in patients treated with aflibercept.

The incidence of reported ATEs in the DME studies from baseline to week 100 was 5% (64 out of 1,262) in patients treated with VABYSMO compared with 5% (32 out of 625) in patients treated with aflibercept.

The incidence of reported ATEs in the RVO studies during the first 6 months was 1.1% (7 out of 641) in patients treated with VABYSMO compared with 1.4% (9 out of 635) in patients treated with aflibercept.

Retinal Vasculitis and/or Retinal Vascular Occlusion
Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of VABYSMO. Healthcare providers should discontinue treatment with VABYSMO in patients who develop these events. Patients should be instructed to report any change in vision without delay.

Adverse Reactions
The most common adverse reactions (≥5%) reported in patients receiving VABYSMO were cataract (15%) and conjunctival hemorrhage (8%).

Pregnancy, Lactation, Females and Males of Reproductive Potential
Based on the mechanism of action of VEGF and Ang-2 inhibitors, there is a potential risk to female reproductive capacity, and to embryo-fetal development. VABYSMO should not be used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VABYSMO and any potential adverse effects on the breastfed child from VABYSMO. Females of reproductive potential are advised to use effective contraception prior to the initial dose, during treatment and for at least 3 months following the last dose of VABYSMO.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in the full VABYSMO Prescribing Information.

- VABYSMO [package insert]. South San Francisco, CA: Genentech, Inc; 2024.
  
  VABYSMO [package insert]. South San Francisco, CA: Genentech, Inc; 2024.
- Data on file. South San Francisco, CA: Genentech, Inc.
  
  Data on file. South San Francisco, CA: Genentech, Inc.
- Baumal CR, et al. Presented at American Academy of Ophthalmology (AAO) 2022. Sep 30–Oct 03 2022.
  
  Baumal CR, et al. Presented at American Academy of Ophthalmology (AAO) 2022. Sep 30–Oct 03 2022.
- Tadayoni R, et al. Presented at Angiogenesis, Exudation, and Degeneration 2023. Feb 10–11 2023.
  
  Tadayoni R, et al. Presented at Angiogenesis, Exudation, and Degeneration 2023. Feb 10–11 2023.
- Regula JT, et al. EMBO Mol Med. 2016;8:1265–1288.
  
  Regula JT, et al. EMBO Mol Med. 2016;8:1265–1288.
- Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635–661.
  
  Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635–661.
- Warmke N, et al. J Diabetes Complications. 2016;30:1643–1650.
  
  Warmke N, et al. J Diabetes Complications. 2016;30:1643–1650.
- Fiedler U, et al. Trends Immunol. 2006;27(12):552–558.
  
  Fiedler U, et al. Trends Immunol. 2006;27(12):552–558.
- Avery RL, et al. Presented at American Association of Ophthalmology (AAO) 2022. Sept 30–Oct 03 2022.
  
  Avery RL, et al. Presented at American Association of Ophthalmology (AAO) 2022. Sept 30–Oct 03 2022.
- Heier J, et al. Lancet. 2022;399(10326):729–740.
  
  Heier J, et al. Lancet. 2022;399(10326):729–740.
- London NJS, et al. Presented at Hawaiian Eye and Retina Meeting 2025. Jan 18–24 2025.
  
  London NJS, et al. Presented at Hawaiian Eye and Retina Meeting 2025. Jan 18–24 2025.
- Wykoff C, et al. Lancet. 2022;399(10326):741–755.
  
  Wykoff C, et al. Lancet. 2022;399(10326):741–755.
- Tadayoni R, et al. Presented at Angiogenesis, Exudation, and Degeneration 2024. Feb 03 2024.
  
  Tadayoni R, et al. Presented at Angiogenesis, Exudation, and Degeneration 2024. Feb 03 2024.
- Heier JS, et al. Presented at American Academy of Ophthalmology Retina Subspecialty Day (AAO-SSD) 2021. Nov 12–13 2021.
  
  Heier JS, et al. Presented at American Academy of Ophthalmology Retina Subspecialty Day (AAO-SSD) 2021. Nov 12–13 2021.
- Goldberg R, et al. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023. April 23–27 2023.
  
  Goldberg R, et al. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023. April 23–27 2023.
- Guymer R, et al. Presented at Angiogenesis, Exudation, and Degeneration 2022. Feb 11–12 2022.
  
  Guymer R, et al. Presented at Angiogenesis, Exudation, and Degeneration 2022. Feb 11–12 2022.
- Baumal CR, et al. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022. May 1–4 2022.
  
  Baumal CR, et al. Presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022. May 1–4 2022.
- Khanani AM, et al. JAMA Ophthalmol. 2020;138(9):964–972.
  
  Khanani AM, et al. JAMA Ophthalmol. 2020;138(9):964–972.
- Sahni J, et al. Ophthalmology. 2019;126(8):1155–1170.
  
  Sahni J, et al. Ophthalmology. 2019;126(8):1155–1170.